The FDA has granted Sofpironium Bromide a standard review (as expected), and confirmed that an advisory committee meeting will not be required. Advisory committees are sometimes convened to assist in the review of complex applications.
In the meantime, an FDA mid-cycle review is due to be completed in Q1, which means we will get further feedback on the progress of the FDA review.
You think FDA?
The FDA has granted Sofpironium Bromide a standard review (as...
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.0¢ |
Change
-0.005(1.45%) |
Mkt cap ! $615.4M | |||
| Open | High | Low | Value | Volume |
| 34.0¢ | 34.0¢ | 32.8¢ | $1.949M | 5.840M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2985 | 33.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 34.0¢ | 420471 | 4 |
View Market Depth
| Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
| BOT (ASX) Chart |